Obinutuzumab Advances Steroid-Sparing Treatment in Childhood Nephrotic Syndrome

FDA approved Gazyva for frequently relapsing or steroid-dependent childhood-onset nephrotic syndrome after randomized phase 3 data showed one-year remission of 95% versus 73% with control therapy. Open-label design, short follow-up, serious adverse events, infection and vaccination concerns, and uncertain long-term relapse control temper the result.